Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer

Documenti analoghi

• Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
  di: Hong, Woo Sung, et al.
  Pubblicazione: (2013)
• The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
  di: Javan-Noughabi, Javad, et al.
  Pubblicazione: (2018)
• Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
  di: Huang L, et al.
  Pubblicazione: (2017-12-01)
• Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
  di: Huang, Liang, et al.
  Pubblicazione: (2017)
• The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
  di: Wu, Xian, et al.
  Pubblicazione: (2021)